Immunological Mechanisms of Disease Training Program
疾病免疫机制培训计划
基本信息
- 批准号:10640277
- 负责人:
- 金额:$ 30.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-05 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
SUMMARY
The Vanderbilt University School of Medicine Immunological Mechanisms of Disease Training
Program (IMDTP) will fill a much-needed gap in the training of basic immunologic mechanisms of
human disease. The clinical translation of basic science immunology to benefit human health now
requires the development of scientists with appreciation of both inflammation and the tissues in which
it occurs. The primary focus of the IMDTP will be to provide pre- and postdoctoral trainees with the
expertise necessary to make novel discoveries in basic immunology and to translate these
discoveries to human disease. The IMDTP will provide trainees a skill set to address how the immune
system is regulated and functions in complex tissues in human disease by integrating basic
immunology and principles of pathology with a particular emphasis on chronic, inflammatory
diseases, and cancer. A long-term goal of the IMDTP will be to not only train the next generation of
research scientists in basic immunology, but to emphasize the importance of using acquired
knowledge as a translational platform on which to develop new therapies and interventions with a
high regard for responsible conduct of research and reproducibility. We plan to use an
interdisciplinary training approach building upon the Vanderbilt University program in Molecular
Pathology and Immunology. The training faculty has been specifically recruited from the greater
Vanderbilt scientific community conducting immunology-based research of chronic inflammatory
diseases and consists of twenty-six highly productive faculty with successful mentoring records. In
order to also allow for the training of future mentors, three mentors are at the Assistant Professor
level. All of the faculty mentors have successful histories training predoctoral and postdoctoral
scientists and have primary interests in immune- and inflammatory-based mechanisms of disease.
These research programs will provide highly developed, diverse, and interdisciplinary training
opportunities. All trainees will acquire and expand their skills in critical thinking, oral and written
communication and interrogation of the literature. These primary functions of the IMDTP will be
facilitated through our bi-weekly immunology and pathology seminar series and annual research
symposium. Training will include participation in courses and modules on both basic immunology and
pathology of disease processes. In addition, we will provide each trainee with the necessary
instruction on responsible conduct in science, rigor and reproducibility in research and information on
alternative career options. Funds are requested to support three predoctoral and two postdoctoral
trainees. Thoughtful mentoring of these trainees, made possible by the IMDTP, will ensure the future
of translational research focused on immunologic mechanisms of disease.
总结
范德比尔特大学医学院疾病免疫机制培训
IMDTP项目将填补在基础免疫机制培训方面急需的空白,
人类疾病基础科学免疫学的临床转化造福人类健康
这需要科学家们对炎症和组织的理解,
它发生。IMDTP的主要重点是为博士前和博士后学员提供
在基础免疫学方面取得新发现并将其翻译成
人类疾病的发现。IMDTP将为学员提供一套技能,以解决免疫系统如何
在人类疾病的复杂组织中,
免疫学和病理学原理,特别强调慢性,炎症
疾病和癌症。IMDTP的长期目标不仅是培养下一代
研究科学家在基础免疫学,但要强调的重要性,
知识作为一个转化平台,在此基础上开发新的疗法和干预措施,
高度重视负责任的研究和可重复性。我们计划使用一个
基于范德比尔特大学分子生物学课程的跨学科培训方法
病理学和免疫学。培训教师是专门从更大的
范德比尔特科学界进行基于免疫学的慢性炎症研究
疾病,并由26个富有成效的教师与成功的指导记录。在
为了也让未来的导师的培训,三个导师在助理教授
水平所有的教师导师都有成功的历史培训博士前和博士后
科学家,并在免疫和炎症为基础的疾病机制的主要兴趣。
这些研究计划将提供高度发达的,多样化的,跨学科的培训
机会所有学员将获得和扩大他们的批判性思维,口头和书面技能
文学的交流与审问。IMDTP的主要功能包括
通过我们的双周免疫学和病理学研讨会系列和年度研究促进
研讨会培训将包括参加基础免疫学和免疫学课程和单元,
疾病过程的病理学。此外,我们将为每位学员提供必要的
关于负责任的科学行为、研究的严谨性和可重复性的指导,
其他职业选择。资金要求支持三个博士前和两个博士后
实习生IMDTP对这些受训者进行的有效指导将确保未来
转化研究的重点是疾病的免疫机制。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AMY S MAJOR其他文献
AMY S MAJOR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AMY S MAJOR', 18)}}的其他基金
Investigating mechanisms of oxidized phospholipid-mediated dysregulation of regulatory T cells in atherosclerosis
研究动脉粥样硬化中氧化磷脂介导的调节性 T 细胞失调的机制
- 批准号:
10648711 - 财政年份:2023
- 资助金额:
$ 30.04万 - 项目类别:
Fc Receptors in Atherosclerosis: Linking Innate and Adaptive Immunity.
Fc§§ 动脉粥样硬化受体:连接先天免疫和适应性免疫。
- 批准号:
10450688 - 财政年份:2021
- 资助金额:
$ 30.04万 - 项目类别:
Fc Receptors in Atherosclerosis: Linking Innate and Adaptive Immunity.
Fc§§ 动脉粥样硬化受体:连接先天免疫和适应性免疫。
- 批准号:
10664909 - 财政年份:2021
- 资助金额:
$ 30.04万 - 项目类别:
Fc Receptors in Atherosclerosis: Linking Innate and Adaptive Immunity.
Fc§§ 动脉粥样硬化受体:连接先天免疫和适应性免疫。
- 批准号:
10259917 - 财政年份:2021
- 资助金额:
$ 30.04万 - 项目类别:
Targeting Tfh Cell Metabolic Regulation in SLE and SLE-Associated Atherosclerosis
针对 SLE 和 SLE 相关动脉粥样硬化的 Tfh 细胞代谢调节
- 批准号:
10029497 - 财政年份:2020
- 资助金额:
$ 30.04万 - 项目类别:
Targeting Tfh Cell Metabolic Regulation in SLE and SLE-Associated Atherosclerosis
针对 SLE 和 SLE 相关动脉粥样硬化的 Tfh 细胞代谢调节
- 批准号:
10609478 - 财政年份:2020
- 资助金额:
$ 30.04万 - 项目类别:
Targeting Tfh Cell Metabolic Regulation in SLE and SLE-Associated Atherosclerosis
针对 SLE 和 SLE 相关动脉粥样硬化的 Tfh 细胞代谢调节
- 批准号:
10380090 - 财政年份:2020
- 资助金额:
$ 30.04万 - 项目类别:
Immunological Mechanisms of Disease Training Program
疾病免疫机制培训计划
- 批准号:
9791561 - 财政年份:2019
- 资助金额:
$ 30.04万 - 项目类别:
Immunological Mechanisms of Disease Training Program
疾病免疫机制培训计划
- 批准号:
10413896 - 财政年份:2019
- 资助金额:
$ 30.04万 - 项目类别:
Targeting the T cell immune synapse in autoimmunity
自身免疫中靶向 T 细胞免疫突触
- 批准号:
9406059 - 财政年份:2017
- 资助金额:
$ 30.04万 - 项目类别:














{{item.name}}会员




